Multiple Sclerosis Therapeutics 4th Cambridge University Press 2012 9780521766272

Home Book Browser

Multiple Sclerosis Therapeutics, Fourth Edition
Editors: Jeffrey A. Cohen and Richard A. Rudick
ISBN 13: 9780521766272
Cambridge University Press 2012 Hard Cover

More Neurology Titles Find the best price on this book

Ratings (1-4 , 4 being the highest):

Organization of information: 4

Usefulness of book: 3.5

Suitable for intended audience: 3.5

Author’s objectives met: 3.5

Significant number of illustrations: 3

Quality of illustrations: 3

Description:

This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors.

Features:

• Figures are used to supplement the information presented, aiding the reader's understanding of key points
• The current status of experimental therapies is summarized, giving readers current knowledge of the most promising therapies being tested
• Contributions from international leaders in the field present a global perspective on the current state of therapeutics and developments

Table of Contents:

Section I. Introduction

1. Aspects of multiple sclerosis that relate to experimental therapeutics
2. The pathology of multiple sclerosis
3. The immunology of multiple sclerosis
4. The genetics of multiple sclerosis
5. The epidemiology of multiple sclerosis

Section II. Clinical Trial Methodology

6. Measures of neurological impairment and disability in multiple sclerosis
7. Assessment of neuropsychological function in multiple sclerosis
8. Health-related quality of life assessment in multiple sclerosis
9. Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging
10. Measures of magnetization transfer
11. Measurement of CNS atrophy
12. Axonal pathology in patients with multiple sclerosis: Evidence from in vivo proton magnetic resonance spectroscopy
13. Imaging of gray matter lesions in multiple sclerosis
14. Functional imaging in multiple sclerosis
15. Diffusion imaging in multiple sclerosis
16. The use of MRI in multiple sclerosis clinical trials
17. Optical coherence tomography to monitor axonal and neuronal integrity in multiple sclerosis
18. The process of drug development and approval in the United States, the European Union, and Asia
19. Selection, interpretation, and development of end-points in multiple sclerosis clinical trials
20. The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis
21. The growing need for alternative clinical trial designs for multiple sclerosis
22. Ethical considerations in multiple sclerosis clinical trials
23. Pharmacogenomics and related discovery-driven approaches in multiple sclerosis
24. Neutralizing antibodies directed against biologic agents to treat multiple sclerosis

Section III. Clinical Trials of Multiple Sclerosis Therapies

25. Interferon beta to treat multiple sclerosis
26. Glatiramer acetate to treat multiple sclerosis
27. Natalizumab to treat multiple sclerosis
28. Mitoxantrone to treat multiple sclerosis
29. Cladribine to treat multiple sclerosis
30. Fingolimod to treat multiple sclerosis
31. Dimethyl fumarate to treat multiple sclerosis
32. Alemtuzumab to treat multiple sclerosis
33. Daclizumab to treat multiple sclerosis
34. Laquinimod to treat multiple sclerosis
35. Teriflunomide to treat multiple sclerosis
36. High-dose methylprednisolone to treat multiple sclerosis
37. Use of immunosuppressants to treat multiple sclerosis
38. Intravenous immunoglobulin to treat multiple sclerosis
39. Plasma exchange treatment for CNS inflammatory demyelinating disease
40. Statins in multiple sclerosis
41. T-cell-based therapies for multiple sclerosis
42. B-cell-based therapies for multiple sclerosis
43. Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis
44. Hemotopoietic stem cell transplantation to treat multiple sclerosis
45. Mesenchymal stem cell transplantation to treat multiple sclerosis
46. Neuroprotection in multiple sclerosis
47. Combination therapy in multiple sclerosis
48. Delfampridine in multiple sclerosis
49. Complementary and alternative treatments in multiple sclerosis
50. The role of chronic cerebrospinal venous insufficiency in multiple sclerosis

Section IV. Therapy in Clinical Practice.

51. Disease-modifying therapy for multiple sclerosis in clinical practice
52. Treatment for patients with primary progressive multiple sclerosis
53. Diagnosis, pathogenesis, and treatment of neuromyelities optica (NMO) spectrum disorders
54. Management of pediatric multiple sclerosis
55. Use of MRI in the clinical management of multiple sclerosis
56. Multiple sclerosis-associated fatigue
57. Management of spasticity
58. Management of bladder and sexual dysfunction in multiple sclerosis
59. Depression in multiple sclerosis
60. Assessment and treatment of pain disorders in multiple sclerosis
61. Management of medical comorbidities in patients with multiple sclerosis
62. Rehabilitation in multiple sclerosis

Index

Color plates appear between pages 398 and 399.

Back to Top